Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Initial Efficacy of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors

NCT06558513 is registered in ClinicalTrials.gov with Evopoint Biosciences Inc. as lead sponsor.

NCT NCT06558513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06558513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Initial Efficacy of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Lead sponsor
Evopoint Biosciences Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 3, 2021
Completion date
August 30, 2025
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced tumor, lymphoma